bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)

Recommended initial regimen for most people
Single-Tablet Regimen

Standard Dose

One tablet once daily without regard to food. Tablet contains 50 mg of the INSTI bictegravir plus 200 mg emtricitabine and 25 mg tenofovir alafenamide (TAF).

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Biktarvy is not recommended for people with CrCl less than 30 mL/min or people with severe liver impairment.


Gilead Sciences, Inc
(800) GILEAD-5 (445–3235)



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments